Cypher outperforms Taxus in head-to-head study
This article was originally published in Clinica
Executive Summary
Johnson and Johnson (J&J) is hoping to rebuild interest in its drug-eluting stent (DES), Cypher, based on the results of the first head-to-head clinical study comparing its device with Boston Scientific's market-leading DES, Taxus.